BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3085684)

  • 1. The fate of [14C]-mesna in the rat.
    Shaw IC; Graham MI; Jones MS
    Arzneimittelforschung; 1986 Mar; 36(3):487-9. PubMed ID: 3085684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylcysteine and sodium 2-mercaptoethane sulfonate as sources of urinary thiol groups in the rat.
    Ormstad K; Ohno Y
    Cancer Res; 1984 Sep; 44(9):3797-800. PubMed ID: 6430554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.
    Ormstad K; Orrenius S; Låstbom T; Uehara N; Pohl J; Stekar J; Brock N
    Cancer Res; 1983 Jan; 43(1):333-8. PubMed ID: 6401168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.
    Shaw IC; Weeks MS
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):933-5. PubMed ID: 3117563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interactions of mesna and dimesna with the sulfate exchange in human red blood cells.
    Reuther H; Kohl M; Wildenauer DB
    Arzneimittelforschung; 1986 Apr; 36(4):763-5. PubMed ID: 3087373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between mesna and selected transition metals in vitro and in vivo.
    Shaw IC; Weeks MS
    Arzneimittelforschung; 1986 Jun; 36(6):997-1000. PubMed ID: 3091043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of orally administered mesna.
    Burkert H; Lücker PW; Wetzelsberger N; Breuel HP
    Arzneimittelforschung; 1984; 34(11):1597-600. PubMed ID: 6441581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of mesna and dimesna in plasma and urine by high-performance liquid chromatography with electrochemical detection.
    James CA; Rogers HJ
    J Chromatogr; 1986 Oct; 382():394-8. PubMed ID: 3097045
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
    Brock N; Pohl J
    IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
    Brock N; Stekar J
    Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat.
    Ormstad K; Uehara N
    FEBS Lett; 1982 Dec; 150(2):354-8. PubMed ID: 6819161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
    James CA; Mant TG; Rogers HJ
    Br J Clin Pharmacol; 1987 May; 23(5):561-8. PubMed ID: 3109461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
    Habs MR; Schmähl D
    Cancer; 1983 Feb; 51(4):606-9. PubMed ID: 6401591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of dimesna to mesna by the isolated perfused rat liver.
    Goren MP; Hsu LC; Li JT
    Cancer Res; 1998 Oct; 58(19):4358-62. PubMed ID: 9766664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and autoradiography of [3H] or [14C]stepholidine.
    Zhang ZD; Zhou CM; Jin GZ; Zhang X; Yang L
    Zhongguo Yao Li Xue Bao; 1990 Jul; 11(4):289-92. PubMed ID: 2104478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
    Verschraagen M; Boven E; Torun E; Hausheer FH; Bast A; van der Vijgh WJ
    Biochem Pharmacol; 2004 Aug; 68(3):493-502. PubMed ID: 15242815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
    Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
    Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.
    Jones MS; Murrell RD; Shaw IC
    Eur J Cancer Clin Oncol; 1985 May; 21(5):553-5. PubMed ID: 3924627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
    el-Yazigi A; Ernst P; al-Rawithi S; Legayada E; Raines DA
    J Clin Pharmacol; 1997 Jul; 37(7):618-24. PubMed ID: 9243355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.
    Verschraagen M; Zwiers TH; Torun E; Donker MG; Reinhoud NJ; Van der Vijgh WJ
    J Pharm Sci; 2003 May; 92(5):1040-50. PubMed ID: 12712424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.